vTv Therapeutics Shares Tumble After FDA Pauses Diabetes-Treatment Study >VTVT

Dow Jones07-27

By Connor Hart

Shares of vTv Therapeutics tumbled after the Food and Drug Administration placed a clinical hold on the company's program studying a treatment for Type 1 diabetes.

After the bell, the stock was down 40% at $12.75. Shares ended the market trading session up 1% at $21.20, putting them up more than 84% since the beginning of the year.

The diabetes-focused biopharmaceutical company on Friday said the FDA's decision came after the discovery of a chromatographic signal in a recent human study of how the treatment--cadisegliatin--was absorbed, distributed, metabolized and excreted couldn't be resolved by standard mass spectroscopy.

The FDA requires a single in vitro study to characterize this signal before the cadisegliatin program, which includes the company's ongoing CATT1 Phase 3 trial in Type 1 diabetes, can resume, the High Point, N.C., company said.

Cadisegliatin is a novel, oral, small-molecule, liver-selective glucokinase activator with first-in-class potential as an adjunct treatment for Type 1 diabetes, the company said.

"We are working diligently with the Agency to resolve the clinical hold and resume enrollment as quickly as possible," Chief Executive Paul Sekhri said.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

July 26, 2024 17:51 ET (21:51 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2454306676?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-27 05:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2454306676","market":"sg","top_or_hot":-1,"title":"vTv Therapeutics Shares Tumble After FDA Pauses Diabetes-Treatment Study >VTVT","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of vTv <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> tumbled after the Food and Drug Administration placed a clinical hold on the company's program studying a treatment for Type 1 diabetes. \n</p>\n<p>\n  After the bell, the stock was down 40% at $12.75. Shares ended the market trading session up 1% at $21.20, putting them up more than 84% since the beginning of the year. \n</p>\n<p>\n  The diabetes-focused biopharmaceutical company on Friday said the FDA's decision came after the discovery of a chromatographic signal in a recent human study of how the treatment--cadisegliatin--was absorbed, distributed, metabolized and excreted couldn't be resolved by standard mass spectroscopy. \n</p>\n<p>\n  The FDA requires a single in vitro study to characterize this signal before the cadisegliatin program, which includes the company's ongoing CATT1 Phase 3 trial in Type 1 diabetes, can resume, the High Point, N.C., company said. \n</p>\n<p>\n  Cadisegliatin is a novel, oral, small-molecule, liver-selective glucokinase activator with first-in-class potential as an adjunct treatment for Type 1 diabetes, the company said. \n</p>\n<p>\n  \"We are working diligently with the Agency to resolve the clinical hold and resume enrollment as quickly as possible,\" Chief Executive Paul Sekhri said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 26, 2024 17:51 ET (21:51 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>vTv Therapeutics Shares Tumble After FDA Pauses Diabetes-Treatment Study >VTVT</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nvTv Therapeutics Shares Tumble After FDA Pauses Diabetes-Treatment Study >VTVT\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-27 05:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Connor Hart \n\n\n \n\n\n  Shares of vTv Therapeutics tumbled after the Food and Drug Administration placed a clinical hold on the company's program studying a treatment for Type 1 diabetes. \n\n\n  After ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2454306676","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454306676","pubTimestamp":1722030660,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of vTv Therapeutics tumbled after the Food and Drug Administration placed a clinical hold on the company's program studying a treatment for Type 1 diabetes.After the bell, the stock was down 40% at $12.75. Shares ended the market trading session up 1% at $21.20, putting them up more than 84% since the beginning of the year.The diabetes-focused biopharmaceutical company on Friday said the FDA's decision came after the discovery of a chromatographic signal in a recent human study of how the treatment--cadisegliatin--was absorbed, distributed, metabolized and excreted couldn't be resolved by standard mass spectroscopy.The FDA requires a single in vitro study to characterize this signal before the cadisegliatin program, which includes the company's ongoing CATT1 Phase 3 trial in Type 1 diabetes, can resume, the High Point, N.C., company said.Cadisegliatin is a novel, oral, small-molecule, liver-selective glucokinase activator with first-in-class potential as an adjunct treatment for","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VTVT":"vTv Therapeutics Inc."},"translate_title":"FDA暂停糖尿病治疗研究后vTv Therapeutics股价暴跌>VTVT","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTVT":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of vTv Therapeutics tumbled after the Food and Drug Administration placed a clinical hold on the company's program studying a treatment for Type 1 diabetes. \n\n\n  After the bell, the stock was down 40% at $12.75. Shares ended the market trading session up 1% at $21.20, putting them up more than 84% since the beginning of the year. \n\n\n  The diabetes-focused biopharmaceutical company on Friday said the FDA's decision came after the discovery of a chromatographic signal in a recent human study of how the treatment--cadisegliatin--was absorbed, distributed, metabolized and excreted couldn't be resolved by standard mass spectroscopy. \n\n\n  The FDA requires a single in vitro study to characterize this signal before the cadisegliatin program, which includes the company's ongoing CATT1 Phase 3 trial in Type 1 diabetes, can resume, the High Point, N.C., company said. \n\n\n  Cadisegliatin is a novel, oral, small-molecule, liver-selective glucokinase activator with first-in-class potential as an adjunct treatment for Type 1 diabetes, the company said. \n\n\n  \"We are working diligently with the Agency to resolve the clinical hold and resume enrollment as quickly as possible,\" Chief Executive Paul Sekhri said. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 26, 2024 17:51 ET (21:51 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454306676"}